Video file
Please connect to access this resource and get a more personalized Campus experience
Executive summary

Discover how ConformalFLASH® is revolutionizing proton therapy and cancer treatment. 

At the 2024 FRPT Congress, Swati Girdhani, Director for Emerging Therapies at IBA, François Vander Stappen, R&D Engineer and Medical Physicist, and Nicolas Gerard, R&D Engineer, presented the latest advancements in ConformalFLASH® on both ProteusPLUS (multi-room) and ProteusONE (single-room) proton therapy platforms.

FLASH therapy delivers ultra-high dose rates (UHDR) of radiation (>40 Gy/s), within a short timeframe. This emerging radiation therapy technique offers key benefits:

  • Spares healthy tissue

  • Reduces treatment time

  • Enhances immune response

  • Targets tumor with precision

     

ConformalFLASH® combines the tissue-sparing benefits of FLASH radiotherapy with the precise dose-shaping capabilities of the proton Bragg peak. ConformalFLASH takes proton therapy to the next level, offering key advantages:

  • Further: ConformalFLASH targets deep-seated tumors using the high beam current and efficiency of Proteus platforms.
  • Faster: ConformalFLASH aims to be the fastest proton therapy solution for cancer treatment.
  • Sharper: ConformalFLASH merges FLASH’s tissue-sparing effects with the Bragg peak’s precise dose delivery.

 

Key highlights:

(00:14) Welcome to 2024 FRPT – ConformalFLASH®

(00:36) IBA proton therapy centers around the world

(01:03) IBA strategic priorities to improve access to proton therapy

(01:38) Benefits of FLASH therapy

(03:00) Advantages of ConformalFLASH®

(04:34) ConformalFLASH® developments on ProteusPLUS

(15:55) First canine trial results with ConformalFLASH at UPenn

(17:23) ConformalFLASH® developments on ProteusONE

(20:30) ConformalFASH® ongoing research with ProteusONE

(25:10) ConformalFLASH timeline from pre-clinical research to patient treatment

 

Want to know more about IBA ConformalFLASH®? Take a closer look here: https://www.iba-protontherapy.com/conformalflash

Disclaimers: 

 ProteusPLUS availability is subject to local listings. Please contact your IBA representative for product availability in your area.

ConformalFLASH® is the registered brand of IBA’s Proton FLASH irradiation solution, which is currently under research and development. ConformalFLASH® will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.

Key content topics
Guest speakers
Swati
Girdhani
Director of Research Collaborations​
IBA